Skip to main content

Research Repository

Advanced Search

A randomised trial evaluating anakinra in early active rheumatoid arthritis.

Scott, Ian C; Ibrahim, Fowzia; Simpson, Gemma; Kowalczyk, Anna; White-Alao, Beverley; Hassell, Andrew; Plant, Michael; Richards, Selwyn; Walker, David; Scott, David L

Authors

Fowzia Ibrahim

Gemma Simpson

Anna Kowalczyk

Beverley White-Alao

Michael Plant

Selwyn Richards

David Walker

David L Scott



Abstract

OBJECTIVES:
The effectiveness of anakinra (interleukin-1 receptor antagonist) in early rheumatoid arthritis (RA) is unknown. We evaluated the efficacy of anakinra (combined with methotrexate) in a randomised clinical trial of early active RA patients.
METHODS:
The Combination Anti-Rheumatic Drugs in Early RA-2 (CARDERA-2) trial was a randomised trial of early (duration <1 year) active RA. Patients were randomised to 12 months of: (1) methotrexate or (2) anakinra-methotrexate. Follow-up lasted 2 years. The primary outcome was erosive progression (changes from baseline in modified Larsen scores). Secondary outcomes were changes from baseline in disease activity score on a 28-joint count (DAS28), health assessment questionnaire (HAQ), and quality of life (EQ-5D) scores alongside ACR responder rates.
RESULTS:
154 patients received the allocated intervention (from 259 screened). Similar Larsen score progression was seen at 12 and 24 months in patients receiving anakinra-methotrexate (mean changes from baseline of 2.50 and 5.10, respectively) and methotrexate monotherapy (mean changes from baseline of 4.16 and 5.20, respectively). Lower improvements in DAS28 and HAQ scores were seen at all time-points in anakinra-methotrexate treated patients; these were significantly less at 24 months (DAS28 p=0.04; HAQ P=0.02). Significantly lower EQ-5D score increases were seen at 12 months with anakinra-methotrexate (p=0.03). Anakinra-methotrexate was associated with more serious adverse events compared with methotrexate monotherapy (11 vs. 6 patients), although this was not significant (p=0.59).
CONCLUSIONS:
Anakinra (combined with methotrexate) is not effective in early, active RA. It provided no clinical benefits beyond methotrexate monotherapy.

Citation

Scott, I. C., Ibrahim, F., Simpson, G., Kowalczyk, A., White-Alao, B., Hassell, A., Plant, M., Richards, S., Walker, D., & Scott, D. L. (2016). A randomised trial evaluating anakinra in early active rheumatoid arthritis. Clinical and Experimental Rheumatology, 34(1), 88-93

Journal Article Type Article
Acceptance Date Sep 2, 2015
Online Publication Date Feb 10, 2016
Publication Date 2016
Deposit Date Mar 6, 2024
Journal Clinical and Experimental Rheumatology
Print ISSN 0392-856X
Electronic ISSN 1593-098X
Publisher Springer Vienna
Peer Reviewed Peer Reviewed
Volume 34
Issue 1
Pages 88-93
Public URL https://keele-repository.worktribe.com/output/525616
Publisher URL https://www.clinexprheumatol.org/abstract.asp?a=9346
PMID 26842950